BeiGene
BGNE
#881
Rank
C$30.08 B
Marketcap
$273.98
Share price
1.71%
Change (1 day)
5.47%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -C$1.2 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -C$1.21 B. In 2023 the company made an earning of -C$1.64 B an increase over its 2022 earnings that were of -C$2.43 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -C$1.2 B-27.25%
2023 -C$1.64 B-32.52%
2022 -C$2.43 B24.39%
2021 -C$1.96 B-13.21%
2020 -C$2.25 B72.69%
2019 -C$1.31 B36.01%
2018 -C$0.96 B616.83%
2017 -C$0.14 B-15.24%
2016 -C$0.16 B107.91%
2015 -C$75.79 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$24.63 M-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.34 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA